Garcia Pablo F, Toneatto Judith, Silvero María Jazmín, Argüello Gerardo A
Instituto de Investigaciones en Físico Química de Córdoba (INFIQC) CONICET-UNC, Departamento de Físico Química, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina.
Laboratory of Nuclear Architecture, Instituto de Biología y Medicina Experimental - CONICET, Ciudad Autónoma de Buenos Aires, Argentina.
Biochim Biophys Acta. 2014 Sep;1840(9):2695-701. doi: 10.1016/j.bbagen.2014.06.010. Epub 2014 Jun 25.
Transferrin is an iron-binding blood plasma glycoprotein that controls the level of free iron in biological fluids. This protein has been deeply studied in the past few years because of its potential use as a strategy of drug targeting to tumor tissues. Chromium complex, Cr(phen)3 (phen=1,10-phenanthroline), has been proposed as photosensitizers for photodynamic therapy (PDT). Thus, we analyzed the binding of chromium complex, Cr(phen)3, to transferrin for a potential delivery of this diimine complex to tumor cells for PDT.
The interaction between Cr(phen)3 and holotransferrin (holoTf) was studied by fluorescence quenching technique, circular dichroism (CD) and ultraviolet (UV)-visible spectroscopy.
Cr(phen)3 binds strongly to holoTf with a binding constant around 10(5)M(-1), that depends on the pH. The thermodynamic parameters indicated that hydrophobic interactions played a major role in the binding processes. The CD studies showed that there are no conformational changes in the secondary and tertiary structures of the protein.
These results suggest that the binding process would occur in a site different from the specific iron binding sites of the protein and would be the same in both protein states. As secondary and tertiary structures of transferrin do not show remarkable changes, we propose that the TfR could recognize the holoTf despite having a chromium complex associated.
Understanding the interaction between Cr(phen)3 with transferrin is relevant because this protein could be a delivery agent of Cr(III) complex to tumor cells. This can allow us to understand further the role of Cr(III) complex as sensitizer in PDT.
转铁蛋白是一种结合铁的血浆糖蛋白,可控制生物体液中游离铁的水平。由于其作为肿瘤组织药物靶向策略的潜在用途,该蛋白在过去几年中得到了深入研究。铬配合物Cr(phen)3(phen = 1,10 - 菲咯啉)已被提议作为光动力疗法(PDT)的光敏剂。因此,我们分析了铬配合物Cr(phen)3与转铁蛋白的结合情况,以期将这种二亚胺配合物潜在地递送至肿瘤细胞用于PDT。
采用荧光猝灭技术、圆二色性(CD)和紫外可见光谱研究了Cr(phen)3与全转铁蛋白(holoTf)之间的相互作用。
Cr(phen)3与holoTf强烈结合,结合常数约为10(5)M(-1),这取决于pH值。热力学参数表明疏水相互作用在结合过程中起主要作用。CD研究表明蛋白质的二级和三级结构没有构象变化。
这些结果表明结合过程将发生在与蛋白质特定铁结合位点不同的位点,并且在两种蛋白质状态下是相同的。由于转铁蛋白的二级和三级结构没有明显变化,我们提出转铁蛋白受体(TfR)尽管与铬配合物结合,但仍可识别holoTf。
了解Cr(phen)3与转铁蛋白之间的相互作用具有重要意义,因为这种蛋白质可能是将Cr(III)配合物递送至肿瘤细胞的载体。这可以使我们进一步了解Cr(III)配合物作为PDT敏化剂的作用。